Skip to main content
Journal cover image

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Publication ,  Journal Article
Griffin, K; Csizmadi, I; Howard, LE; Pomann, G-M; Aronson, WJ; Kane, CJ; Amling, CL; Cooperberg, MR; Terris, MK; Beebe-Dimmer, J; Freedland, SJ
Published in: Cancer Causes Control
March 2019

PURPOSE: We aimed to study the associations between androgen-deprivation therapy (ADT)-induced weight changes and prostate cancer (PC) progression and mortality in men who had undergone radical prostatectomy (RP). METHODS: Data from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort were used to study the associations between weight change approximately 1-year post-ADT initiation and metastases, castration-resistant prostate cancer (CRPC), all-cause mortality (ACM), and PC-specific mortality (PCSM) in 357 patients who had undergone RP between 1988 and 2014. We estimated hazard ratios (HR) and 95% confidence intervals (95% CI) using covariate-adjusted Cox regression models for associations between weight loss, and weight gains of 2.3 kg or more, and PC progression and mortality post-ADT. RESULTS: During a median (IQR) follow-up of 81 (46-119) months, 55 men were diagnosed with metastases, 61 with CRPC, 36 died of PC, and 122 died of any cause. In multivariable analysis, weight loss was associated with increases in risks of metastases (HR 3.13; 95% CI 1.40-6.97), PCSM (HR 4.73; 95% CI 1.59-14.0), and ACM (HR 2.16; 95% CI 1.25-3.74) compared with mild weight gains of ≤ 2.2. Results were slightly attenuated but remained statistically significant in analyses that accounted for competing risks of non-PC death. Estimates for the associations between weight gains of ≥ 2.3 kg and metastases (HR 1.58; 95% CI 0.73-3.42), CRPC (HR 1.33; 95% CI 0.66-2.66), and PCSM (HR 2.44; 95% CI 0.84-7.11) were elevated, but not statistically significant. CONCLUSIONS: Our results suggest that weight loss following ADT initiation in men who have undergone RP is a poor prognostic sign. If confirmed in future studies, testing ways to mitigate weight loss post-ADT may be warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Causes Control

DOI

EISSN

1573-7225

Publication Date

March 2019

Volume

30

Issue

3

Start / End Page

259 / 269

Location

Netherlands

Related Subject Headings

  • Weight Loss
  • Prostatic Neoplasms
  • Prostatectomy
  • Proportional Hazards Models
  • Prognosis
  • Middle Aged
  • Male
  • Humans
  • Follow-Up Studies
  • Epidemiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Griffin, K., Csizmadi, I., Howard, L. E., Pomann, G.-M., Aronson, W. J., Kane, C. J., … Freedland, S. J. (2019). First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes Control, 30(3), 259–269. https://doi.org/10.1007/s10552-019-1133-5
Griffin, Kagan, Ilona Csizmadi, Lauren E. Howard, Gina-Maria Pomann, William J. Aronson, Christopher J. Kane, Christopher L. Amling, et al. “First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.Cancer Causes Control 30, no. 3 (March 2019): 259–69. https://doi.org/10.1007/s10552-019-1133-5.
Griffin K, Csizmadi I, Howard LE, Pomann G-M, Aronson WJ, Kane CJ, et al. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes Control. 2019 Mar;30(3):259–69.
Griffin, Kagan, et al. “First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.Cancer Causes Control, vol. 30, no. 3, Mar. 2019, pp. 259–69. Pubmed, doi:10.1007/s10552-019-1133-5.
Griffin K, Csizmadi I, Howard LE, Pomann G-M, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes Control. 2019 Mar;30(3):259–269.
Journal cover image

Published In

Cancer Causes Control

DOI

EISSN

1573-7225

Publication Date

March 2019

Volume

30

Issue

3

Start / End Page

259 / 269

Location

Netherlands

Related Subject Headings

  • Weight Loss
  • Prostatic Neoplasms
  • Prostatectomy
  • Proportional Hazards Models
  • Prognosis
  • Middle Aged
  • Male
  • Humans
  • Follow-Up Studies
  • Epidemiology